Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F9 | P00740 | 5/20 | 0.49 |
| ▸ | F10 | P00742 | 14/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12546495 | 0.89 | F9 (0.43) | F9F10PTGS2 | |
| SCHEMBL1950193 | 0.89 | F9 (0.47) | F9F10 | |
| SCHEMBL1950270 | 0.87 | F9 (0.63) | F9F10 | |
| SCHEMBL12546785 | 0.86 | F9 (0.41) | F9F10PTGS2 | |
| SCHEMBL12548406 | 0.85 | F9 (0.44) | F9F10 | |
| SCHEMBL12548582 | 0.85 | F9 (0.42) | F9F10PTGS2 | |
| SCHEMBL1950675 | 0.83 | F9 (0.39) | F9F10PTGS2 | |
| SCHEMBL1950677 | 0.83 | F9 (0.39) | F9F10PTGS2 | |
| SCHEMBL1947995 | 0.83 | F9 (0.39) | F9F10PTGS2 | |
| SCHEMBL1947998 | 0.83 | F9 (0.39) | F9F10PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8987242-B2 | Morpholinone compounds as factor IXA inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-03-24 | — | — | US | disclosed |
| US-8987242-B2 | Morpholinone compounds as factor IXA inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-03-24 | — | — | US | disclosed |
| EP-2473491-B1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | MOCHIDA PHARM CO LTD (JP) | 2013-07-17 | — | — | EP | disclosed |
| EP-2473491-B1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | MOCHIDA PHARM CO LTD (JP) | 2013-07-17 | — | — | EP | disclosed |
| US-20110135650-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | MERCK SHARP & DOHME LLC | 2011-06-09 | — | — | US | disclosed |
| US-20110135650-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | MERCK SHARP & DOHME LLC | 2011-06-09 | — | — | US | disclosed |
| WO-2011025565-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2011-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110135650-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | SERPINC1, F9, F8 | F9 2/4885F10 9/4885PTGS2 2450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.